Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHVN NASDAQ:IMAB NASDAQ:IMCR NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHVNBiohaven$15.35-1.1%$14.49$12.79▼$55.70$1.64B0.982.03 million shs999,656 shsIMABI-Mab$4.16-2.1%$3.03$0.60▼$5.90$347.06M1.384.86 million shs1.40 million shsIMCRImmunocore$32.22-0.1%$33.34$23.15▼$39.33$1.62B0.77313,571 shs210,634 shsWVEWAVE Life Sciences$9.60-3.3%$8.24$5.04▼$16.74$1.58B-0.951.66 million shs1.23 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHVNBiohaven-1.01%-1.68%-2.33%+3.53%-62.56%IMABI-Mab-2.12%-18.27%+104.93%+220.00%+255.56%IMCRImmunocore-0.06%-2.16%-3.82%-11.70%-10.85%WVEWAVE Life Sciences-3.32%-5.42%+17.65%+57.89%+71.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHVNBiohaven3.7779 of 5 stars4.53.00.00.03.02.50.6IMABI-Mab2.9219 of 5 stars3.55.00.00.02.71.70.0IMCRImmunocore1.5521 of 5 stars3.31.00.00.01.72.50.0WVEWAVE Life Sciences4.7576 of 5 stars4.51.00.04.83.34.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHVNBiohaven 3.07Buy$54.23253.20% UpsideIMABI-Mab 3.00Buy$7.0068.27% UpsideIMCRImmunocore 2.55Moderate Buy$56.8976.56% UpsideWVEWAVE Life Sciences 2.93Moderate Buy$20.27111.11% UpsideCurrent Analyst Ratings BreakdownLatest IMAB, IMCR, BHVN, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025IMABI-MabLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$8.008/28/2025IMABI-MabBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/25/2025IMCRImmunocoreJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$48.008/21/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.008/20/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.008/19/2025BHVNBiohavenBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$59.00 ➝ $60.008/12/2025BHVNBiohavenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $30.008/12/2025BHVNBiohavenLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $50.008/12/2025BHVNBiohavenMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$63.00 ➝ $54.008/12/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$57.00 ➝ $52.008/12/2025BHVNBiohavenBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $49.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHVNBiohavenN/AN/AN/AN/A$1.27 per shareN/AIMABI-Mab$3.89M87.33N/AN/A$2.41 per share1.73IMCRImmunocore$310.20M5.23N/AN/A$7.71 per share4.18WVEWAVE Life Sciences$108.30M14.11N/AN/A$0.88 per share10.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHVNBiohaven-$846.42M-$7.66N/AN/AN/AN/A-270.65%-143.70%11/11/2025 (Estimated)IMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.65%-18.58%11/13/2025 (Estimated)IMCRImmunocore-$51.09M-$0.40N/AN/AN/A-5.70%-5.40%-1.93%11/5/2025 (Estimated)WVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest IMAB, IMCR, BHVN, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025Q2 2025IMABI-Mab-$0.10-$0.07+$0.03-$0.07N/AN/A8/11/2025Q1 2025BHVNBiohaven-$1.94-$1.94N/A-$1.94$0.41 millionN/A8/7/2025Q2 2025IMCRImmunocore-$0.21-$0.20+$0.01-$0.20$122.96 million$130.65 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHVNBiohavenN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHVNBiohaven1.913.823.82IMABI-MabN/A22.8222.82IMCRImmunocore1.015.895.86WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHVNBiohaven88.78%IMABI-Mab38.38%IMCRImmunocore84.50%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipBHVNBiohaven16.00%IMABI-Mab22.10%IMCRImmunocore10.40%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHVNBiohaven239105.79 million88.86 millionOptionableIMABI-Mab38081.66 million63.61 millionOptionableIMCRImmunocore32050.39 million45.15 millionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableIMAB, IMCR, BHVN, and WVE HeadlinesRecent News About These CompaniesWave Life Sciences Ltd. (WVE) Gains Momentum With Multiple RNA WinsAugust 29 at 7:55 PM | finance.yahoo.comWAVE Life Sciences Ltd. $WVE Shares Purchased by Charles Schwab Investment Management Inc.August 29 at 3:14 AM | marketbeat.comWAVE Life Sciences Ltd. $WVE Shares Acquired by Affinity Asset Advisors LLCAugust 28 at 9:02 AM | marketbeat.comWAVE Life Sciences Ltd. $WVE Stock Position Raised by Martingale Asset Management L PAugust 28 at 4:51 AM | marketbeat.comGregory Verdine Sells 10,000 Shares of WAVE Life Sciences (NASDAQ:WVE) StockAugust 27 at 7:20 AM | insidertrades.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Shares Sold by Maven Securities LTDAugust 23, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $1.02 Million Stock Position in WAVE Life Sciences Ltd. $WVEAugust 19, 2025 | marketbeat.com29,572 Shares in WAVE Life Sciences Ltd. (NASDAQ:WVE) Bought by Wealthedge Investment Advisors LLCAugust 18, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading Up 7.8% - Still a Buy?August 17, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells $85,192.70 in StockAugust 15, 2025 | marketbeat.comWave Life Sciences moved to not rated at JPMorganAugust 15, 2025 | msn.comInsider Selling: WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Sells 9,670 Shares of StockAugust 14, 2025 | insidertrades.comWave Life Sciences Shareholders Approve Key ProposalsAugust 11, 2025 | msn.comWave Life Sciences Earnings Call: Clinical Advances Amid Financial ChallengesAugust 9, 2025 | theglobeandmail.comKen Takanashi Sells 4,872 Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) StockAugust 8, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Director Ken Takanashi Sells 4,872 SharesAugust 8, 2025 | insidertrades.comWAVE Life Sciences (NASDAQ:WVE) Now Covered by Canaccord Genuity GroupAugust 5, 2025 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Holdings Trimmed by TD Asset Management IncAugust 5, 2025 | marketbeat.comWave Life Sciences is a new Buy at Canaccord Genuity on near-term catalystsAugust 5, 2025 | msn.comCanaccord Genuity Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationAugust 5, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMAB, IMCR, BHVN, and WVE Company DescriptionsBiohaven NYSE:BHVN$15.35 -0.17 (-1.07%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$15.42 +0.06 (+0.40%) As of 08/29/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.I-Mab NASDAQ:IMAB$4.16 -0.09 (-2.12%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.24 +0.08 (+1.80%) As of 08/29/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Immunocore NASDAQ:IMCR$32.22 -0.02 (-0.06%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$32.20 -0.02 (-0.06%) As of 08/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.WAVE Life Sciences NASDAQ:WVE$9.60 -0.33 (-3.32%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.60 +0.01 (+0.05%) As of 08/29/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
